Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VIR-5525 + pembrolizumab
- Development stage
- Unknown
- Lead developer
- Vir Biotechnology
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
VIR-5525 + pembrolizumab is a combination investigational therapy for solid tumors expressing EGFR, currently in Phase 1 clinical trials. VIR-5525 is a dual-masked T-cell engager (TCE) that utilizes PRO-XTEN masking technology to selectively activate within the tumor microenvironment, aiming to mitigate damage to healthy cells and reduce toxicity. It targets the epidermal growth factor receptor (EGFR) to direct T-cell-mediated killing of cancer cells. Pembrolizumab is a monoclonal antibody and immune checkpoint inhibitor that blocks PD-1, preventing tumor cells from evading immune attack and enhancing T-cell response. This combination is intended to leverage both direct T-cell targeting of EGFR-positive tumors (via VIR-5525) and immune checkpoint blockade (via pembrolizumab), potentially improving anti-tumor efficacy in advanced, locally advanced, or metastatic solid malignancies with EGFR expression. The lead developer is Vir Biotechnology[1][2][3][4][5][6][7].
- Brand names
- Keytruda
- Other names
- VIR-5525 + pembrolizumab
02
Targets
EGFR T790M (Epidermal growth factor receptor T790M mutant)PDCD1 (Programmed cell death protein 1 receptor)CD3 (T-cell surface glycoprotein CD3)
Beyond the preview
Go deeper on VIR-5525 + pembrolizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VIR-5525 + pembrolizumab.